EGFR-Mutated Lung Cancer Perspectives

Hossein Borghaei, DO, MS, division chief of thoracic medical oncology at Fox Chase Cancer Center, spoke with Healio about recent advances in the management of EGFR-mutated lung cancer.

In this video, Borghaei discusses:

• intracranial control with the third-generation tyrosine kinase inhibitor osimertinib (Tagrisso, AstraZeneca);
• phase 3 data presented at the ASCO Annual Meeting that showed treatment with a first-generation TKI, erlotinib (Tarceva; Genentech, Astellas Oncology), plus a VEGFR inhibitor, ramucirumab (Cyramza, Eli Lilly), improved PFS among patients with metastatic disease;
• research investigating other novel treatment combinations, including frontline therapy with chemotherapy plus an oral TKI, as well as chemoimmunotherapy with or without a VEGFR inhibitor;
• optimal treatment strategies for locally-advanced disease; and
• progress toward a “cure.”